Limits...
Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Nishizawa S, Inagaki T, Iba A, Kikkawa K, Kodama Y, Matsumura N, Kohjimoto Y, Hara I - Springerplus (2014)

Bottom Line: Change in T-score from baseline differed significantly between the two groups (P=0.009).While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score.ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan ; Department of Urology, Rinku General Medical Center, Osaka, Japan.

ABSTRACT
The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy. Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months. Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen (ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups (P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group. While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.

No MeSH data available.


Related in: MedlinePlus

Change in T-score in the ZA-treated and control groups. (a) T-score at baseline and 12 months in each group; (b) Mean ± SE change in T-score from baseline in the two groups. SE, standard error of the mean; ZA, zoledronic acid; Ctrl, control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4197198&req=5

Fig1: Change in T-score in the ZA-treated and control groups. (a) T-score at baseline and 12 months in each group; (b) Mean ± SE change in T-score from baseline in the two groups. SE, standard error of the mean; ZA, zoledronic acid; Ctrl, control.

Mentions: At 1 year after treatment, patients on ZA maintained their T-score (P = 0.74), while control patients experienced a significant decrease in T-score (−3.9%, P = 0.001). Change in T-score from baseline differed significantly between the two groups (P = 0.009) (Figure 1). We performed analysis as stratified by baseline T-score, since the decrease in BMD was considered to contribute to the risk of SRE, especially among patients with lower BMD at baseline. In ZA-treated patients, the lower baseline T-score group (T-score ≤0; n = 6) tended to have an increase in T-score when compared with the normal baseline T-score group (T-score >0; n = 13) (P = 0.06), while no difference was revealed in control patients when comparing the lower and normal baseline T-score group (P = 0.57) (Figure 2a). An inverse correlation was demonstrated between baseline and change in T-score in ZA-treated patients (r = −0.49, P = 0.03). By contrast, these variables didn’t correlate with one another in the control patients (r = 0.11, P = 0.61) (Figure 2b).Figure 1


Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Nishizawa S, Inagaki T, Iba A, Kikkawa K, Kodama Y, Matsumura N, Kohjimoto Y, Hara I - Springerplus (2014)

Change in T-score in the ZA-treated and control groups. (a) T-score at baseline and 12 months in each group; (b) Mean ± SE change in T-score from baseline in the two groups. SE, standard error of the mean; ZA, zoledronic acid; Ctrl, control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4197198&req=5

Fig1: Change in T-score in the ZA-treated and control groups. (a) T-score at baseline and 12 months in each group; (b) Mean ± SE change in T-score from baseline in the two groups. SE, standard error of the mean; ZA, zoledronic acid; Ctrl, control.
Mentions: At 1 year after treatment, patients on ZA maintained their T-score (P = 0.74), while control patients experienced a significant decrease in T-score (−3.9%, P = 0.001). Change in T-score from baseline differed significantly between the two groups (P = 0.009) (Figure 1). We performed analysis as stratified by baseline T-score, since the decrease in BMD was considered to contribute to the risk of SRE, especially among patients with lower BMD at baseline. In ZA-treated patients, the lower baseline T-score group (T-score ≤0; n = 6) tended to have an increase in T-score when compared with the normal baseline T-score group (T-score >0; n = 13) (P = 0.06), while no difference was revealed in control patients when comparing the lower and normal baseline T-score group (P = 0.57) (Figure 2a). An inverse correlation was demonstrated between baseline and change in T-score in ZA-treated patients (r = −0.49, P = 0.03). By contrast, these variables didn’t correlate with one another in the control patients (r = 0.11, P = 0.61) (Figure 2b).Figure 1

Bottom Line: Change in T-score from baseline differed significantly between the two groups (P=0.009).While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score.ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan ; Department of Urology, Rinku General Medical Center, Osaka, Japan.

ABSTRACT
The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy. Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months. Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen (ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups (P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group. While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.

No MeSH data available.


Related in: MedlinePlus